Immunosuppression remains the cornerstone of management of CTD-ILD; the drugs include corticosteroids and corticosteroid-sparing medications, such as azathioprine, cyclosporine, cyclophosphamide, and methotrexate.
However, the PANTHER-IPF study challenges this protocol; the trial was prematurely terminated as a result of increased morbidity and mortality, much of which was due to pulmonary infection. It is now estimated that corticosteroids may increase the risk for serious infection fourfold.
If a patient shows a progressive deterioration in lung function or no slowing in lung function decline, discontinuation of immunosuppressive medications should be considered.
Learn more about CT-ILD treatment.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Rheumatoid Arthritis Interstitial Lung Disease Management - Medscape - Apr 05, 2021.